Clinical trials
Advanced or Metastatic Solid Tumors clinical trials
Below are recruiting advanced or metastatic solid tumors clinical trials, each written for real people, not researchers. We’re tracking 4,859 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05532696RecruitingPhase 1/Phase 2
Testing ABT-101 for advanced solid tumors and HER2-mutant lung cancer
This study tests ABT-101, a new experimental treatment, in people with advanced solid tumors. A second part specifically looks at people with non-small cell lung cancer (NSCLC) that has HER2 mutations, to see how well the treatment works and how safe it is.
TaichungAges 18 years+ - NCT05732831RecruitingPhase 1/Phase 2
Study drug for tumors with MTAP loss
This Phase 1/2 trial tests TNG462 (with or without pembrolizumab, depending on the plan) in solid tumors that have lost MTAP. The goal is to check safety and learn whether the treatment can help people with these specific tumor changes.
Palo Alto, CaliforniaAges 18 years+ - NCT05768139RecruitingPhase 1/Phase 2
Testing a new targeted drug for advanced solid tumors with PI3Kα mutation
This trial tests tersolisib, a new targeted medicine, in adults with advanced or hard-to-remove solid cancers. It focuses on tumors that have a specific genetic change (PI3Kα mutation) to see how well the treatment works and what side effects it causes.
Los Angeles, CaliforniaAges 18 years+ - NCT05784688RecruitingPhase 1/Phase 2
TU2218 with Keytruda for advanced solid tumors
This trial studies TU2218 taken with Keytruda (pembrolizumab) in adults with advanced solid cancers that have limited treatment options. The goal is to see if the combination can shrink tumors and is safe enough to keep using.
San Antonio, TexasAges 18 years+ - NCT05785741RecruitingPhase 1/Phase 2
DB-1310 for advanced solid tumors after standard treatment fails
This early-phase study tests DB-1310 in people with advanced or metastatic solid cancers that have come back or worsened after standard treatments. It aims to find the safest dose and whether it can help shrink tumors or slow cancer growth.
Sacramento, CaliforniaAges 18 years+ - NCT05837767Recruiting
Radiation study for tumors that spread to soft tissue areas
This study looks at how a planned form of palliative radiation therapy treats certain solid cancers that have spread outside the brain to larger soft-tissue areas. It may help shrink tumors and relieve symptoms, but it also asks you to meet specific safety and treatment-timing rules.
Basking Ridge, New JerseyAges 18 years+ - NCT05880043RecruitingPhase 1/Phase 2
IV NK cell treatment for advanced cancers that returned
This Phase 1/2 study tests an intravenous (IV) immune-cell therapy made from donors (allogeneic NK cells) to treat advanced solid tumors, relapsed/refractory non-Hodgkin lymphoma, or multiple myeloma. It may help by targeting cancer cells more directly, but early-phase trials mainly focus on safety and finding the right dosing.
SeoulAges 19 years+ - NCT05892718RecruitingPhase 1
Testing an immune drug for hard-to-treat cancers
This early-phase study tests HCB101, an immune-targeting drug, to see if it is safe and can shrink certain solid tumors or non-Hodgkin lymphoma. It may help people whose cancer has returned or stopped responding to standard treatments.
Port Saint Lucie, FloridaAges 18 years+ - NCT05914116RecruitingPhase 1/Phase 2
Early study of DB-1311 with BNT324 for advanced solid tumors
This Phase 1/2a study tests a combination treatment (DB-1311 with BNT324) in people with advanced or metastatic solid cancers that have grown despite standard treatments. It aims to find a safe dose and look for signs the treatment can shrink tumors or slow growth.
Tucson, ArizonaAges 18 years+ - NCT06026410RecruitingPhase 1
KO-2806 for advanced solid tumors
This trial tests a new drug called KO-2806, alone or with other treatments, for people with advanced solid tumors that have specific gene changes (like HRAS or KRAS mutations). It may help if standard treatments have stopped working.
Phoenix, ArizonaAges 18 years+ - NCT06040541RecruitingPhase 1
Study of RMC-9805 for KRAS G12D solid tumors
This trial tests an experimental pill (RMC-9805) for people with solid tumors that have a specific KRAS G12D mutation. It's for those who have already tried other treatments and need new options.
Sacramento, CaliforniaAges 18 years+ - NCT06132503RecruitingPhase 1
Testing LP-284 for advanced lymphomas and solid tumors
This trial tests an experimental drug called LP-284 in people with certain advanced lymphomas or solid tumors that have not responded to standard treatments. The goal is to see if it is safe and works against these cancers.
West Valley City, UtahAges 18 years+ - NCT06209580RecruitingPhase 1/Phase 2
Testing AMT-253 for advanced solid tumors
This study tests an experimental drug AMT-253 in people with advanced solid tumors (like melanoma) that have progressed despite prior treatment. The goal is to see if the drug can help shrink or slow the cancer.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06234423RecruitingPhase 1
A study of CUSP06 for advanced solid tumors
This study tests a new drug called CUSP06 for people with advanced solid tumors, especially ovarian cancer that has stopped responding to platinum chemotherapy. It may help if standard treatments no longer work.
Denver, ColoradoAges 18 years+ - NCT06245330RecruitingPhase 1/Phase 2
Study of AST-001 for advanced solid tumors
This trial is testing a new drug called AST-001 for people with advanced solid tumors (including pancreatic cancer) that have not responded to standard treatments. The study aims to find the right dose and see how well the drug works.
Changchun, JinlinAges 18–70 - NCT06386146RecruitingPhase 1/Phase 2
New pill for advanced cancers with TP53 Y220C mutation
This trial tests a new pill called JAB-30355 for people with advanced cancers that have a specific genetic change (TP53 Y220C). It's for those who have already tried other treatments and are looking for a new option.
Denver, ColoradoAges 18 years+ - NCT06403735RecruitingPhase 1
Study of QLC1101 for advanced solid tumors with KRAS G12D mutation
This trial tests a new drug, QLC1101, for people with advanced solid tumors that have a specific genetic change called KRAS G12D. It may be an option if you have tried other treatments or cannot take them.
Guangzhou, GuangdongAges 18 years+ - NCT06425926RecruitingPhase 1/Phase 2
Study of GIM-531 in advanced solid tumors
This study tests a new oral drug, GIM-531, alone and in combination with an anti-PD-1 therapy for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if it is safe and effective.
Scottsdale, ArizonaAges 18 years+ - NCT06431594RecruitingPhase 1
Study of a new drug for advanced solid tumors
This trial tests a new drug called Mocertatug Rezetecan for people with advanced solid tumors that have stopped responding to standard treatments. It targets a protein called B7-H4 on cancer cells to try to slow or shrink the tumor.
Birmingham, AlabamaAges 18 years+ - NCT06452160RecruitingPhase 1
Study of BGC515 for advanced solid tumors
This trial tests an experimental drug called BGC515 for people with advanced solid tumors, including mesothelioma and EHE, that have not responded to standard treatments. The drug works by targeting a specific cell signaling pathway (Hippo) that may be involved in cancer growth.
Houston, TexasAges 18 years+ - NCT06469008RecruitingPhase 1
Study of BL-B16D1 for advanced head and neck cancer and other solid tumors
This study tests a new drug, BL-B16D1, for people with advanced head and neck cancer or other solid tumors that have not been helped by standard treatments. The goal is to see if the drug is safe and effective.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06478251RecruitingPhase 1
Engineered immune cells for KRAS-mutated advanced solid tumors
This trial tests a new type of cell therapy that uses your own immune cells, specially trained to attack cancer cells with a KRAS G12V or G12D mutation. It may be an option if you have advanced solid tumors that no longer respond to standard treatments.
Hangzhou, ZhejiangAges 18–75 - NCT06484556RecruitingPhase 1
T cell therapy for KRAS-mutated advanced solid tumors
This trial tests a personalized T cell therapy designed to target cancer cells with specific KRAS mutations (G12V or G12D). It may be an option for people with advanced solid tumors who have exhausted standard treatments.
Wuhan, HubeiAges 18–75 - NCT06484790RecruitingPhase 1
Engineered T cell therapy for KRAS-mutated advanced solid tumors
This trial tests a personalized T cell therapy designed to target specific KRAS mutations (G12V or G12D) in people with advanced solid tumors who have no standard treatment options left. The treatment involves collecting your own immune cells, engineering them to recognize and attack cancer cells with these mutations, and then infusing them back into you.
Tianjin, Tianjin MunicipalityAges 18–75
Hear when a new Advanced or Metastatic Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for advanced or metastatic solid tumors?
- Yes. Clin2 currently lists 4,859 recruiting advanced or metastatic solid tumors studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advanced or metastatic solid tumors trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advanced or metastatic solid tumors trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Locally Advanced or Metastatic Solid Tumors
- Advanced/Metastatic Solid Tumors
- Locally Advanced (Unresectable) or Metastatic Solid Tumors
- Locally Advanced/Metastatic Solid Tumors
- Patients With Advanced Solid Tumors
- Mesothelin-positive Advanced Malignant Solid Tumors
- Recurrent or Metastatic Solid Tumors
- Advanced Solid Tumor
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.